Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX:PAR) has disclosed that an independent interim analysis conducted by TrialKey Pty Ltd confirms statistically significant results favouring injectable pentosan polysulfate sodium (iPPS) over placebo in the rest-of-world (ROW) cohort of its PARA_OA_012 Phase 3 knee osteoarthritis study, with the findings providing a basis to assess a potential ROW trial.
Key Points
- TrialKey's independent interim analysis, dated 16 November 2026, confirmed statistically significant results favouring iPPS for Weekly Average Daily Pain at Day 112, WOMAC physical function, and Patient Global Impression of Change in the ROW cohort.
- The ROW cohort in PARA_OA_012 comprised participants from Australia, Hong Kong and Moldova.
- The overall interim futility result remains unchanged, with no clear treatment advantage overall or in the US.
- The Board's proposal to preserve the iPPS program has not yet been presented to or approved by creditors, and further development remains subject to funding, the administration process and applicable approvals.
- Paradigm plans to consult the US FDA on PARA_OA_012 results and further consider a development pathway in the US.
Independent Analysis Findings for the ROW Cohort
The interim report was prepared by TrialKey Pty Ltd, a wholly owned subsidiary of Pathkey.AI Limited (ASX:PKY), based on de-identified participant data provided by Paradigm. In the ROW cohort, iPPS showed statistically significant benefits over placebo for Weekly Average Daily Pain (wADP) at Day 112, WOMAC physical function, and Patient Global Impression of Change (PGIC). WOMAC pain also favoured iPPS, though that result was not statistically significant. The findings are consistent with Paradigm's internal ROW analysis announced on 15 October 2026, which reported an adjusted treatment difference of −1.105 points on the 0–10 pain scale in favour of iPPS, with a 95% confidence interval of −1.733 to −0.476 and p=0.0007.
US Cohort Result and Identified Operational Issues
In the US cohort, the iPPS and placebo groups showed similar responses, with placebo-group improvement greater in the US than in ROW. TrialKey identified a higher proportion of scheduled injections recorded as not given in the US, as well as gaps in pain records. The review noted that treatment delivery, data completeness and site performance require further assessment. Expectations, natural changes in symptoms, prior pain treatment and differences in care or follow-up may also contribute to the observed treatment responses, though none has been established as a specific cause. TrialKey's report states there is a data-based reason to investigate another trial outside the USA.
Proposed ROW Trial Pathway and Administration Process
The Board's proposal aims to preserve iPPS and establish a funded path forward combining clinical development, regulatory engagement, funding and restructuring options. Specific countries and sites for a potential ROW trial would be assessed on their ability to recruit suitable participants, deliver treatment and collect reliable data. The scope and timing of the program would be determined alongside funding arrangements and the administration process. The Board's proposal has not been presented to or approved by creditors, and there is no certainty that a proposal will be accepted, funding secured or further development commenced. Any proposed deed of company arrangement remains subject to applicable creditor decision and other required approvals.





Please wait processing your request...